[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE248912T1 - Therapeutische antiangiogenische zusammensetzungen und verfahren - Google Patents

Therapeutische antiangiogenische zusammensetzungen und verfahren

Info

Publication number
ATE248912T1
ATE248912T1 AT96936842T AT96936842T ATE248912T1 AT E248912 T1 ATE248912 T1 AT E248912T1 AT 96936842 T AT96936842 T AT 96936842T AT 96936842 T AT96936842 T AT 96936842T AT E248912 T1 ATE248912 T1 AT E248912T1
Authority
AT
Austria
Prior art keywords
methods
antiangiogenic compositions
therapeutic
therapeutic antiangiogenic
compositions
Prior art date
Application number
AT96936842T
Other languages
English (en)
Inventor
Michael S O'reilly
M Judah Folkman
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/740,168 external-priority patent/US5854205A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE248912T1 publication Critical patent/ATE248912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
AT96936842T 1995-10-23 1996-10-23 Therapeutische antiangiogenische zusammensetzungen und verfahren ATE248912T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US583595P 1995-10-23 1995-10-23
US2307096P 1996-08-02 1996-08-02
US2626396P 1996-09-17 1996-09-17
US08/740,168 US5854205A (en) 1995-10-23 1996-10-22 Therapeutic antiangiogenic compositions and methods
PCT/US1996/016925 WO1997015666A1 (en) 1995-10-23 1996-10-23 Therapeutic antiangiogenic compositions and methods

Publications (1)

Publication Number Publication Date
ATE248912T1 true ATE248912T1 (de) 2003-09-15

Family

ID=27485527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96936842T ATE248912T1 (de) 1995-10-23 1996-10-23 Therapeutische antiangiogenische zusammensetzungen und verfahren

Country Status (16)

Country Link
US (9) US6630448B2 (de)
EP (1) EP0857210B1 (de)
JP (2) JP3840262B2 (de)
KR (1) KR19990066981A (de)
CN (1) CN1202932A (de)
AT (1) ATE248912T1 (de)
AU (1) AU717277B2 (de)
BR (1) BR9611174A (de)
CZ (1) CZ117798A3 (de)
DE (1) DE69629826T2 (de)
DK (1) DK0857210T3 (de)
ES (1) ES2206602T3 (de)
IL (1) IL124153A (de)
NO (1) NO981803L (de)
NZ (1) NZ321356A (de)
WO (1) WO1997015666A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
ES2206602T3 (es) 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
AU2004202593B2 (en) * 1995-10-23 2008-01-03 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DE19615710A1 (de) * 1996-04-22 1997-10-23 Forssmann Wolf Georg Verfahren zur Gewinnung und Anwendung eines biologisch aktiven Eiweisstoffes - Kollagenfragment HF-COLL-18/514cf - in partiell aufgereinigter und synthetischer Form aus Körperflüssigkeiten zur Beeinflussung des Zellwachstums und der Diagnose von Kollagenerkrankungen sowie der Osteoporose
AU3968597A (en) 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
EP0979290A2 (de) 1997-04-28 2000-02-16 Aventis Pharma S.A. Adenoviren - vermittelte intratumorale verabreichung eines angiogenese - antagonists zur behandlung der tumoren
AU8918898A (en) * 1997-08-25 1999-03-16 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibi tors
AU9673998A (en) * 1997-10-01 1999-04-23 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
AU1598599A (en) * 1997-11-20 1999-06-15 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
KR20010015869A (ko) * 1997-12-08 2001-02-26 베쓰 이스라엘 디코니스 메디칼 센터 레스틴 및 그의 사용 방법
US6852691B1 (en) 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO1999039741A2 (en) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
AU3199999A (en) * 1998-03-24 1999-10-18 Children's Medical Center Corporation Endostatin derived peptides with anti-angiogenic and anti-cancer activity
US6121236A (en) 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
ES2224627T3 (es) * 1998-03-27 2005-03-01 The University Of Kansas Medical Center El uso de dominios aislados de colageno tipo iv para modificar interacciones celulares y tisulares.
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
EP1100941A2 (de) * 1998-07-27 2001-05-23 Valentis Inc. Anti-angiogenesis plasmide und applikationssysteme , und methode für ihre herstellung und verwendung
JP2002523036A (ja) * 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション イムノフュージンとしての新脈管形成インヒビターの発現および輸送
US6201104B1 (en) 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU4342000A (en) * 1999-04-13 2000-11-14 Merck & Co., Inc. Soluble recombinant endostatin and method of making same from (streptomyces sp)
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
US6369021B1 (en) * 1999-05-07 2002-04-09 Ecolab Inc. Detergent composition and method for removing soil
SG87828A1 (en) * 1999-09-03 2002-04-16 Univ Singapore Small peptides having potent anti-angiogenic activity
US20020086007A1 (en) * 2000-10-13 2002-07-04 Sim Kim Lee Angiogenesis-inhibiting peptides and proteins and methods of use
ATE446772T1 (de) 2001-01-05 2009-11-15 Viromed Ltd Zusammensetzungen zur gentherapie rheumatoider arthritis, die ein gen, das für ein anti- angiogenes protein oder teile davon kodiert, enthalten
AU2002240463A1 (en) 2001-02-22 2002-09-12 Novartis Ag Use of endostatin in the treatment of ocular neovascularization
ITMI20010394A1 (it) * 2001-02-27 2002-08-27 Univ Degli Studi Milano Peptidi ad attivita' antiangiogenica
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
PL363311A1 (en) 2001-04-24 2004-11-15 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnfalpha
US20040219204A1 (en) * 2002-12-19 2004-11-04 Huang Ken Shi Kun Method of treating angiogenic tissue growth
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7348001B2 (en) * 2003-08-12 2008-03-25 Dyax Corp. Tie1-binding ligands
KR100579660B1 (ko) * 2003-08-18 2006-05-15 정인식 제미니바이러스 발현시스템을 이용한 재조합 신생혈관생성억제 단백질의 제조방법
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
AU2004269399A1 (en) 2003-08-29 2005-03-10 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
EP2301963A1 (de) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptidverbindungen zur Hemmung von Angiogenese und Tumorwachstum
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7662945B2 (en) * 2005-02-01 2010-02-16 Massachusetts Eye & Ear Infirmary Neostatins
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1934867A2 (de) * 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
EP2463305B1 (de) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antikörper zu OX-2/CD200 und deren Verwendungen
JP4745851B2 (ja) * 2006-02-09 2011-08-10 キヤノン株式会社 撮像装置
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
KR20140137463A (ko) 2007-02-01 2014-12-02 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
EP1972639A3 (de) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
EP2062920A3 (de) 2007-11-21 2009-06-17 Peter Hornbeck Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
KR101263424B1 (ko) 2008-04-04 2013-05-14 조대웅 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2400990A2 (de) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
US8218068B2 (en) * 2009-04-01 2012-07-10 Omnivision Technologies, Inc. Exposing pixel groups in producing digital images
JP2013500991A (ja) 2009-07-31 2013-01-10 オーエスアイ・ファーマシューティカルズ，エルエルシー ｍＴＯＲ阻害剤および血管新生阻害剤併用療法
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8833064B2 (en) * 2009-11-06 2014-09-16 Basf Corporation Small engine layered catalyst article and method of making
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8828343B2 (en) * 2010-03-05 2014-09-09 Basf Corporation Carbon monoxide conversion catalyst
US8698496B2 (en) * 2010-09-20 2014-04-15 The General Hospital Corporation Method for two-dimensional correlation magnetic resonance spectroscopy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012122334A2 (en) * 2011-03-08 2012-09-13 The Johns Hopkins University Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN104411332B (zh) 2012-03-30 2018-11-23 索伦托治疗有限公司 与vegfr2结合的全人抗体
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013158617A1 (en) * 2012-04-16 2013-10-24 The Board Of Trustees Of The University Of Illinois Endostatin peptides and use thereof
KR101539700B1 (ko) * 2012-09-05 2015-07-28 아주대학교산학협력단 연골세포 유래 세포외 기질막을 이용한 신생혈관질환 치료용 조성물 및 각막 또는 결막 이식재
US10683550B2 (en) 2014-04-04 2020-06-16 Crown Bioscience, Inc. (Taicang) HNF4G-RSPO2 fusion gene and use thereof in treatment of cancer
CN113717274B (zh) * 2015-07-27 2023-11-28 上海贺普药业股份有限公司 一种肿瘤抑制肽
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
EP4026849A1 (de) 2016-09-26 2022-07-13 Ensemble Group Holdings Verfahren zur beurteilung und behandlung von krebs bei menschen mit dysregulierten lymphatischen systemen unter verwendung einer kombination aus vegfr-3 und pd-1- oder pd-l1-inhibitoren
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836391A (ja) 1981-08-07 1983-03-03 Sankyo Co Ltd 新生理活性物質アンジオスタチン
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
US4889806A (en) * 1987-04-15 1989-12-26 Washington University Large DNA cloning system based on yeast artificial chromosomes
US5302390A (en) * 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
WO1993016716A1 (en) * 1992-02-24 1993-09-02 Northwestern University Method and composition for inhibiting angiogenesis
US5491129A (en) 1992-07-30 1996-02-13 Yeda Research And Development Co. Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
US5643783A (en) * 1993-12-01 1997-07-01 President And Fellows Of Harvard College Collagen and uses therefor
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DE69535405T2 (de) * 1994-04-26 2007-11-15 Children's Medical Center Corp., Boston Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
AU3724495A (en) 1994-09-13 1996-03-29 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
ES2206602T3 (es) 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CN1060521C (zh) 1997-09-10 2001-01-10 徐根兴 一种人实体肿瘤血管内皮细胞增殖抑制因子的基因克隆方法及在抗肿瘤血管再生治疗中的应用

Also Published As

Publication number Publication date
US20030219426A1 (en) 2003-11-27
US20020086352A1 (en) 2002-07-04
BR9611174A (pt) 1999-09-14
US20040102372A1 (en) 2004-05-27
US20020127595A1 (en) 2002-09-12
DE69629826D1 (de) 2003-10-09
ES2206602T3 (es) 2004-05-16
KR19990066981A (ko) 1999-08-16
CZ117798A3 (cs) 1998-08-12
EP0857210A1 (de) 1998-08-12
US7655458B2 (en) 2010-02-02
NO981803D0 (no) 1998-04-22
JP2004236662A (ja) 2004-08-26
US6630448B2 (en) 2003-10-07
DK0857210T3 (da) 2004-01-12
US6746865B1 (en) 2004-06-08
US20020155987A1 (en) 2002-10-24
AU7466696A (en) 1997-05-15
JP2002501362A (ja) 2002-01-15
CN1202932A (zh) 1998-12-23
US20030087393A1 (en) 2003-05-08
US20020123458A1 (en) 2002-09-05
US6764995B2 (en) 2004-07-20
DE69629826T2 (de) 2004-07-01
US7101979B1 (en) 2006-09-05
US6544758B2 (en) 2003-04-08
IL124153A (en) 2008-03-20
US7179608B2 (en) 2007-02-20
WO1997015666A1 (en) 1997-05-01
JP3840262B2 (ja) 2006-11-01
AU717277B2 (en) 2000-03-23
NO981803L (no) 1998-06-17
EP0857210B1 (de) 2003-09-03
NZ321356A (en) 1998-11-25

Similar Documents

Publication Publication Date Title
DE69629826D1 (de) Therapeutische antiangiogenische zusammensetzungen und verfahren
ATE181913T1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)- benzopyran für die behandlung von proliferativer erkrankungen
PT950100E (pt) Mutantes do factor 2 de crescimento dos ceranocitos (fcc-2 ou factor 12 de crescimento dos fibroblastos fcf-12)
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
NO974943L (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DK1140969T3 (da) Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
DE60032783D1 (en) Thrombopoietinmimetika
DE60025632D1 (de) Thrombopoietin-mimetika
ATE241354T1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO934218D0 (no) Inhibitorer av cathepsin G og elastase for forhindring avbindevevsnedbrytning
DE69611452D1 (de) Benzothiophenderivate
FI955721A0 (fi) Urokinaasityyppisen plasminogeenin aktivaattorin inhibiittoreiden ilmentämiseksi
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69209773D1 (de) Depolymerisation von konjugierten Dienpolymeren
ID26524A (id) Turunan-turunan kroman tersubstitusi karboksil bermanfaat sebagai agonis beta-3 adrenoreseptor
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ZA9610073B (en) Method of using beta-interferons to treat restenosis
BR9713828A (pt) Tratamento de tumores altamente vasculares

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0857210

Country of ref document: EP